Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.

Yogurtcu, Osman N; Funk, Patrick R; Forshee, Richard A; Anderson, Steven A; Marks, Peter W; Yang, Hong

Yogurtcu, Osman N; Funk, Patrick R; Forshee, Richard A; Anderson, Steven A; Marks, Peter W; Yang, Hong.

Afiliación

Yogurtcu ON; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
Funk PR; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
Forshee RA; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
Anderson SA; Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
Marks PW; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
Yang H; Office of the Center Director, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.

Vaccine X ; 14: 100325, 2023 Aug.

Article en En | MEDLINE | ID: mdl-37324525

Palabras clave

Benefit-risk analysis; COVID-19 vaccine; FDA; Males; Myocarditis; Pericarditis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Vaccine X Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google